A method of producing a composition for a treatment of cardiovascular and cerebrovascular diseases is provided. The method includes the following steps of: a) according to a ratio of 1 lt, adding 2 ml 36.5-37.5% formic aldehyde solution to 998 ml sterile and 0.85-0.95% isotonic sodium chloride solution to obtain a mixture, mixing the mixture thoroughly and obtaining an aldehyde solution with a final concentration of 0.073-0.075% by weight for injection, and b) storing the composition obtained in a dark place at a temperature of 15-35° C.

A method of producing a composition for a treatment of cardiovascular and cerebrovascular diseases is provided. The method includes the following steps of: a) according to a ratio of 1 lt, adding 2 ml 36.5-37.5% formic aldehyde solution to 998 ml sterile and 0.85-0.95% isotonic sodium chloride solution to obtain a mixture, mixing the mixture thoroughly and obtaining an aldehyde solution with a final concentration of 0.073-0.075% by weight for injection, and b) storing the composition obtained in a dark place at a temperature of 15-35° C.

The invention relates to medicine and veterinary medicine, and more specifically, to pharmacology, and can be used to treat viral infections caused by RNA viruses that have a lipid envelope, in particular coronaviral infections, AIDS and hepatitis C. The invention extends the range of drugs for the claimed purpose. The technical result is the creation of a drug having an intracellular, antiseptic effect that activates the production of endogenous formaldehyde in the body of a human and animals without having side effects and toxicity. The technical result is achieved by the use of an immunomodulating drug comprising 0.073-0.075% of formaldehyde in an isotonic solution of sodium chloride as a drug for intramuscular injections with a single 5 ml injection dosage for treating coronaviral and retroviral infections and hepatitis C.

The invention relates to medicine and veterinary medicine, and more specifically, to pharmacology, and can be used to treat viral infections caused by RNA viruses that have a lipid envelope, in particular coronaviral infections, AIDS and hepatitis C. The invention extends the range of drugs for the claimed purpose. The technical result is the creation of a drug having an intracellular, antiseptic effect that activates the production of endogenous formaldehyde in the body of a human and animals without having side effects and toxicity. The technical result is achieved by the use of an immunomodulating drug comprising 0.073-0.075% of formaldehyde in an isotonic solution of sodium chloride as a drug for intramuscular injections with a single 5 ml injection dosage for treating coronaviral and retroviral infections and hepatitis C.

The present invention relates to a condensation product obtainable by reaction of a1) at least one aromatic system or heteroaromatic system, a2) at least one carbonyl compound, a3) if appropriate at least one sulfonating agent, and a4) if appropriate at least one urea derivative, where the condensation product has a molecular weight Mw of at least 300 g/mol, for use in a method for the treatment of COVID-19. The invention further relates to a use of the condensation product in a therapeutic method for the treatment of COVID-19; to a use of the condensation product as disinfectant against the virus SARS-CoV-2; and to a use of the condensation product for the production of a medicament which is an antiviral agent against SARS-CoV-2.

The present invention relates to a condensation product obtainable by reaction of a1) at least one aromatic system or heteroaromatic system, a2) at least one carbonyl compound, a3) if appropriate at least one sulfonating agent, and a4) if appropriate at least one urea derivative, where the condensation product has a molecular weight Mw of at least 300 g/mol, for use in a method for the treatment of COVID-19. The invention further relates to a use of the condensation product in a therapeutic method for the treatment of COVID-19; to a use of the condensation product as disinfectant against the virus SARS-CoV-2; and to a use of the condensation product for the production of a medicament which is an antiviral agent against SARS-CoV-2.

The present disclosure relates, in some embodiments, to an immunogenic compositions for the treatment of cancer, methods of preparing an immunogenic composition for the treatment of cancer, and methods of treating cancer subjects with an immunogenic composition.

Some embodiments of the present disclosure relate to an immunogenic composition operable as a treatment of cancer in a subject having a subject weight, the immunogenic composition including: an immunoactive tissue extract comprising a protein composition, wherein the immunogenic composition has a final concentration of the protein composition of about 6 mg to about 10 mg of the protein composition per kg of the subject weight; an immune response activator comprising a BCG solution, wherein the immunogenic composition has a final concentration of the immune response activator of about 0.525 to about 0.725 mg of the BCG solution per mL of the immunogenic composition; and an immune response mitigator comprising a formaldehyde solution, wherein the immunogenic composition has a final concentration of the formaldehyde solution of about 0.005% to about 0.035%.

The present disclosure relates, in some embodiments, to an immunogenic compositions for the treatment of cancer, methods of preparing an immunogenic composition for the treatment of cancer, and methods of treating cancer subjects with an immunogenic composition.

Some embodiments of the present disclosure relate to an immunogenic composition operable as a treatment of cancer in a subject having a subject weight, the immunogenic composition including: an immunoactive tissue extract comprising a protein composition, wherein the immunogenic composition has a final concentration of the protein composition of about 6 mg to about 10 mg of the protein composition per kg of the subject weight; an immune response activator comprising a BCG solution, wherein the immunogenic composition has a final concentration of the immune response activator of about 0.525 to about 0.725 mg of the BCG solution per mL of the immunogenic composition; and an immune response mitigator comprising a formaldehyde solution, wherein the immunogenic composition has a final concentration of the formaldehyde solution of about 0.005% to about 0.035%.

The present disclosure relates, in some embodiments, to an immunogenic compositions for the treatment of cancer, methods of preparing an immunogenic composition for the treatment of cancer, and methods of treating cancer subjects with an immunogenic composition.

Some embodiments of the present disclosure relate to an immunogenic composition operable as a treatment of cancer in a subject having a subject weight, the immunogenic composition including: an immunoactive tissue extract comprising a protein composition, wherein the immunogenic composition has a final concentration of the protein composition of about 6 mg to about 10 mg of the protein composition per kg of the subject weight; an immune response activator comprising a BCG solution, wherein the immunogenic composition has a final concentration of the immune response activator of about 0.525 to about 0.725 mg of the BCG solution per mL of the immunogenic composition; and an immune response mitigator comprising a formaldehyde solution, wherein the immunogenic composition has a final concentration of the formaldehyde solution of about 0.005% to about 0.035%.

There is provided a composition comprising an organic material and at least a first surfactant which following addition of an aqueous solution to the composition can form a biphasic system, wherein the biphasic system is useful for the treatment of or prevention of hoof infections. Also provided is a biphasic system useful for the treatment of or prevention of hoof infections, wherein the biphasic system comprises the composition and an aqueous phase wherein the composition is dispersed as droplets within the aqueous phase.